Peptide Side Effects
What is proven in human trials, what has only been seen in animals, and what is theoretical. Organized by compound, with the warning signs that mean stop and call a doctor.
- Most common: injection-site reactions
- Best data: approved drugs like GLP-1s
- Research peptides: little human data

Educational content only, not medical advice. If you have a severe or worrying symptom, contact a healthcare provider or emergency services now.
Three levels of evidence
"Side effect" means very different things depending on where the information comes from.
Proven in human trials
Approved drugs like semaglutide, tirzepatide and bremelanotide (Vyleesi) have measured side-effect rates from large trials.
Strong
Seen in animals
Findings from rodent or cell studies. Worth knowing, but not proof of what happens in people.
Preclinical
Theoretical
Concerns reasoned from how a compound works, never tested. Not proven, not ruled out.
Mechanism only
For BPC-157, TB-500, MOTS-c, CJC-1295, Ipamorelin, Selank, Semax, Epithalon, KPV and DSIP, there is no randomized human trial establishing long-term safety. That gap is the biggest risk of all.
Side effects by compound
Scan for the one you care about.
| Compound | Common | Serious or watch for | Evidence |
|---|---|---|---|
| Any injection | Redness, swelling, itching, bruising | Infection, allergic reaction | Well known |
| Semaglutide, tirzepatide | Nausea, diarrhea, vomiting, constipation | Pancreatitis, gallbladder problems, dehydration | Large trials |
| PT-141 (bremelanotide) | Nausea, flushing, headache | Blood pressure rise, skin darkening | Trials (Vyleesi) |
| GH-releasing peptides (CJC-1295, Ipamorelin, Sermorelin) | Flushing, water retention, hunger, tingling hands | Higher blood sugar; long-term unknown | Small studies |
| MK-677 (not a peptide) | Hunger, water retention | Higher blood sugar, lower insulin sensitivity | 2-year trial |
| Melanotan II | Nausea, flushing, darker skin and freckles | New or changing moles | Case reports |
| BPC-157, TB-500 | Injection-site reactions | Theoretical tumor-growth concern | Animal / theory |
GLP-1 drugs: the best-measured side effects
Mostly stomach-related, worst while the dose is being raised.
Stomach side effects overall: 74% vs 48%. 7% stopped because of side effects, vs 3% on placebo.
Wilding et al., N Engl J Med 2021 (PMID 33567185)
Diarrhea 19 to 23%, vomiting 8 to 12% across doses. 4 to 7% stopped because of side effects, vs 3% on placebo.
Jastreboff et al., N Engl J Med 2022 (PMID 35658024)
Both appear in the prescribing information. Rapid weight loss itself raises gallstone risk.
See semaglutide and tirzepatide
PT-141 and Melanotan
Related peptides that act on melanocortin receptors, with very different evidence.
Measured in trials
In the approval trials: nausea 40% (vs 1% on placebo), flushing 20%, headache 11%. Blood pressure rose up to about 6 mmHg for several hours after each dose. Skin darkening in 1% at up to 8 doses a month, far more with daily use.
Label limits: one dose per 24 hours, 8 per month
Never approved anywhere
Nausea, flushing and darker skin and freckles are common. Dermatology case reports describe new moles appearing quickly and existing moles changing, including reports of melanoma in users.
Watch: any new or changing mole
Growth hormone peptides
- Blood sugar: in a 2-year trial of MK-677 in older adults, fasting glucose rose and insulin sensitivity fell. Reviews of GH secretagogues report the same pattern.
- Hunger, cortisol, prolactin: older GHRPs like GHRP-6 raise all three. Ipamorelin was selective in animal studies, with little effect on cortisol.
- Water retention, joint aches, tingling hands: typical of anything that raises GH.
- Cancer: a theoretical concern, since GH and IGF-1 promote cell growth. No human data confirms or rules it out.
Mixing up CJC-1295 with and without DAC is a common way people overdose.

BPC-157 and TB-500: the theoretical concerns
BPC-157 is thought to work partly by promoting new blood vessel growth. The same process can, in principle, help a tumor grow. That is a mechanism-based concern, not a demonstrated human outcome. See BPC-157 human studies.
TB-500 is a fragment of thymosin beta-4. Cancer researchers study thymosin beta-4 because higher levels are linked to tumor growth and spread in lab and animal work. Nobody has shown TB-500 causes cancer in people, but anyone with a current or past cancer should treat this as a real reason to avoid it. See TB-500 human studies.
Red flags: stop and get help
Don't wait to see if these settle on their own.
Allergic reaction
Hives, swelling of the face or throat, or trouble breathing. Call emergency services.
Infected injection site
Spreading redness, heat, pus, or fever. Needs prompt medical care.
Severe stomach pain
Especially on a GLP-1, pain that won't ease or spreads to the back can mean pancreatitis.
Chest pain or severe headache
Including after PT-141. Seek care right away.
A new or changing mole
Especially with Melanotan. Get it checked by a dermatologist.
Can't keep fluids down
Ongoing vomiting or diarrhea risks dehydration and kidney strain.
Quality is its own risk
Research peptides are not made under FDA oversight. A vial that doesn't match its label, or carries bacteria or endotoxin, can cause problems no matter which peptide it is supposed to be.
- Check the COA: identity, purity and endotoxin. See how to read a COA.
- Prescription route: under the October 2026 draft HHS policy, compounded BPC-157, TB-500 and four others must be fully tested, including sterility and endotoxin.

Monitor, don't guess
- Baseline labs before you start, then a recheck. Fasting glucose and IGF-1 matter most for GH peptides.
- Log every dose and any reaction, so a pattern shows up early.
- Start low and change one thing at a time.
See the peptide bloodwork guide. The dashboard logs doses and symptoms, and Lab Analysis tracks your markers.

Frequently asked questions
What are the most common peptide side effects?
For any injected peptide, the most common are injection-site reactions: redness, mild swelling, itching or bruising. Beyond that it depends on the compound: GLP-1 drugs like semaglutide and tirzepatide mainly cause nausea, diarrhea, vomiting and constipation; PT-141 causes nausea and flushing; growth hormone peptides can cause water retention, hunger and higher blood sugar.
How common is nausea on semaglutide or tirzepatide?
Very common. In the main semaglutide 2.4mg obesity trial, 44% had nausea versus about 10% on placebo. In the main tirzepatide trial, 25 to 33% had nausea depending on dose, versus about 6% on placebo. It is usually worst while the dose is being increased and eases over time.
Do growth hormone peptides cause cancer?
No human data shows that GH-releasing peptides such as CJC-1295, Ipamorelin or Sermorelin cause cancer. Because growth hormone and IGF-1 promote cell growth, there is a theoretical concern, and no long-term human data rules it out. People with a current or past cancer should discuss this with their oncologist before using anything that raises GH.
Is TB-500 linked to tumor growth?
TB-500 is a fragment of thymosin beta-4, which cancer researchers study because higher levels are associated with tumor growth and spread in lab and animal research. That has not been shown in people taking TB-500, but it is a reason for anyone with a cancer history to avoid it.
What are the side effects of PT-141?
In the trials behind its approval as Vyleesi, bremelanotide caused nausea in 40% of users, flushing in 20% and headache in 11%. Blood pressure rises slightly for several hours after each dose, and some users develop darkened patches of skin, especially with frequent dosing. The label limits use to one dose per 24 hours and eight per month.
Does Melanotan II cause moles or melanoma?
Melanotan II reliably darkens skin and freckles. Dermatology case reports describe new moles appearing quickly and existing moles changing in users, including reports of melanoma. It has never been approved anywhere, and any new or changing mole should be checked by a dermatologist.
When should I stop a peptide and see a doctor?
Get help right away for signs of an allergic reaction (hives, face or throat swelling, trouble breathing), an infected injection site (spreading redness, heat, pus, fever), severe stomach pain that will not ease, chest pain or a severe headache, a new or changing mole, or vomiting and diarrhea that stop you keeping fluids down.
How reliable is safety data for research peptides?
For most research peptides, including BPC-157, TB-500, MOTS-c, CJC-1295, Ipamorelin, Selank, Semax, Epithalon, KPV and DSIP, there is no randomized human trial establishing long-term safety. That means the true side-effect profile, the right human dose and the effects of long-term use are not known the way they are for approved drugs.
Catch problems early
Log doses, symptoms and labs in one place, so you can see what changed and when. Free.
Sources
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. PMID 33567185
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. PMID 35658024
- VYLEESI (bremelanotide) prescribing information: adverse reactions, blood pressure and hyperpigmentation. drugs.com
- Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. 2008. PMID 18981483
- Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018. PMID 28400207
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PMID 9849822
- Eruptive Melanocytic Nevi: A Review. PMID 31119650
- Thymosin β4: a potential molecular target for tumor therapy. PMID 22856429
This content is for informational purposes only and is not medical advice. It describes trial data, animal findings and theoretical concerns, and should not be read as evidence that any peptide does or does not cause a specific outcome in you. Always consult a qualified healthcare provider, and report concerning symptoms promptly.